Early-Stage Preclinical Validation Of Therapeutic Leads For Diseases Of Interest To The Niddk (R01)
Main page content
Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01)
Purpose: The overarching goal of this Funding Opportunity Announcement (FOA) is to translate basic science research into knowledge and tools that can be utilized to provide strong justification for later-phase therapeutics discovery and development efforts in health-related outcomes relevant to the National Institute of Diabetes and Digestive and Kidney Diseases...
Deadline: every June 5, October 5 until May 8, 2019